Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00674700 |
Recruitment Status :
Completed
First Posted : May 8, 2008
Results First Posted : May 19, 2016
Last Update Posted : May 19, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Allergic Rhinitis | Drug: 300 IR house dust mites allergen extract tablet Drug: 500 IR house dust mites allergen extract tablet Drug: Placebo tablet | Phase 2 Phase 3 |
Allergic rhinitis is a high-prevalence disease in many developed countries, affecting about 10 to 20% of the general population. House dust mite allergens are known to cause perennial allergic rhinitis.
In designing the present study, the guidelines proposed by the World Allergy Organization (WAO) task force for methodology of immunotherapy studies have been taken into consideration.
After a 2-month screening period, patients will be administered the dose of 300 IR- or 500 IR-house dust mite allergen-based tablets or placebo for a period of 12 months. The carry-over effect will be evaluated after a treatment-free follow up period of 12 months.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 509 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, DBPC, Multi-national Phase II/III Study of the Safety and Efficacy of Two Doses of Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Adult Patients Suffering From HDM Allergic Rhinitis |
Study Start Date : | October 2007 |
Actual Primary Completion Date : | February 2009 |
Actual Study Completion Date : | February 2010 |
Arm | Intervention/treatment |
---|---|
Active Comparator: 300 IR
300 IR house dust mites allergen extract tablet
|
Drug: 300 IR house dust mites allergen extract tablet
One sublingual tablet daily for one year
Other Name: Sublingual immunotherapy tablet |
Active Comparator: 500 IR
500 IR house dust mites allergen extract tablet
|
Drug: 500 IR house dust mites allergen extract tablet
One sublingual tablet daily for one year
Other Name: Sublingual immunotherapy tablet |
Placebo Comparator: Placebo
Placebo tablet
|
Drug: Placebo tablet
One sublingual tablet daily for one year
Other Name: Sublingual placebo tablet |
- Average Adjusted Symptom Score (AAdSS) During the Year 1 Primary Period [ Time Frame: Last 3 months of Year 1 ]
The AAdSS is derived from the daily Rhinoconjunctivitis Total Symptom Scores (RTSS), based on the severity of the 4 rhinitis symptoms: sneezing, rhinorrhoea, nasal pruritus and nasal congestion, each graded on a 4-point scale (0-3; 0: absent, 1: mild, 2: moderate, 3: severe).
It ranges from 0 to 12, the higher the score the more severe the rhinitis.
- Average Rhinitis Total Symptom Score (ARTSS) [ Time Frame: Last 3 months of Year 1 ]The Rhinitis Total Symptom Score (RTSS) evaluates the presence and severity of the 4 rhinitis symptoms: sneezing, rhinorrhoea, nasal pruritus and nasal congestion (absence of symptom (0), mild symptom (1), moderate symptom (2), severe symptom (3)). It ranges from 0 to 12, the higher the score the more severe the rhinitis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female outpatients aged 18 to 50 years (inclusive).
- Patients who have been informed of the nature and aims of the study and have given their written consent
- Patients must be in general good health as determined by past medical history, physical examination and safety laboratory tests.
- Female patients of childbearing potential are eligible
- Negative urine pregnancy test on female patients of childbearing potential.
- House dust mite-related allergic rhinitis for at least 1 year.
- Sensitised to D. pteronyssinus or D. farinae (positive SPT with wheal diameter greater than 3 mm and a specific IgE level ≥ 0.7 kU/L).
- Baseline ARTSS > 5 (after completion of the 7-day daily record card).
- Patients who are willing to comply with the protocol.
- Patients who are able to understand the information given and the text of the consent form, and who are able to complete the daily record card and the RQLQ.
Exclusion Criteria:
- Whatever the considered allergens, co-sensitisation leading to clinically relevant allergic rhinitis, sinusitis, conjunctivitis or asthma likely to significantly change the symptoms of the patient throughout the study (that means patient symptomatic to another allergen than house dust mites).
- Patients with any nasal condition that could confound the efficacy or safety assessments (for example nasal polyposis).
- Patients sensitised to cat or dog allergens and living with these animals at home.
- Pregnant, breast-feeding / lactating or sexually active women of childbearing potential who are not using a medically accepted contraceptive method.
- Asthma requiring treatment other than beta-2 inhaled agonists. Patients with intermittent asthma not necessitating inhaled or systemic corticoid treatment may be included (corresponding to the Global Initiative for Asthma [GINA] Step 1).
- Patients treated with systemic, nasal or inhaled steroids (whatever the indication) within 4 weeks before Visit 1.
- Patients treated with long acting systemic steroids (whatever the indication) within 12 weeks before Visit 1 and before Visit 2.
- FEV1 < 80% of predicted value at Visit 1.
- Patients who received allergy specific immunotherapy for house dust mites in the last 10 years.
- Patients at risk of non-compliance.
- Participation in any clinical study within the 12 weeks before Visit 1.
- Investigators, co-investigators, as well as their children or spouses and all the study collaborators should not be enrolled in the study.
- Any change in environmental measures for allergen avoidance during the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00674700
Study Chair: | Karl-Christian BERGMANN, MD | Allergie-Centrum-Charité / ECARF |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Stallergenes Greer |
ClinicalTrials.gov Identifier: | NCT00674700 |
Other Study ID Numbers: |
VO57.07 |
First Posted: | May 8, 2008 Key Record Dates |
Results First Posted: | May 19, 2016 |
Last Update Posted: | May 19, 2016 |
Last Verified: | April 2016 |
House dust mites allergy |
Rhinitis Rhinitis, Allergic Respiratory Tract Infections Infections Nose Diseases Respiratory Tract Diseases Otorhinolaryngologic Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Immunomodulating Agents Immunologic Factors Physiological Effects of Drugs |